J
5.51
0.17 (3.18%)
| Previous Close | 5.34 |
| Open | 5.35 |
| Volume | 722,122 |
| Avg. Volume (3M) | 443,881 |
| Market Cap | 82,657,720 |
| Price / Book | 1.05 |
| 52 Weeks Range | |
| Earnings Date | 3 Mar 2025 - 7 Mar 2025 |
| Diluted EPS (TTM) | -4.75 |
| Total Debt/Equity (MRQ) | 2.47% |
| Current Ratio (MRQ) | 7.61 |
| Operating Cash Flow (TTM) | -57.95 M |
| Levered Free Cash Flow (TTM) | -36.91 M |
| Return on Assets (TTM) | -40.92% |
| Return on Equity (TTM) | -71.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Jasper Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
0.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.25 |
|
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.28% |
| % Held by Institutions | 98.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (JMP Securities, 1,170.42%) | Buy |
| Median | 55.50 (907.26%) | |
| Low | 40.00 (HC Wainwright & Co., 625.95%) | Buy |
| Average | 55.25 (902.72%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 10.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Jan 2025 | 40.00 (625.95%) | Buy | 7.05 |
| JMP Securities | 10 Jan 2025 | 70.00 (1,170.42%) | Buy | 7.05 |
| 06 Jan 2025 | 70.00 (1,170.42%) | Buy | 20.87 | |
| RBC Capital | 09 Jan 2025 | 48.00 (771.14%) | Buy | 6.99 |
| 23 Dec 2024 | 68.00 (1,134.12%) | Buy | 22.12 | |
| BMO Capital | 06 Dec 2024 | 63.00 (1,043.38%) | Buy | 22.48 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2025 | Announcement | Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria |
| 06 Jan 2025 | Announcement | Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025 |
| 02 Dec 2024 | Announcement | Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma |
| 13 Nov 2024 | Announcement | Jasper Therapeutics to Participate at Upcoming Investor Conferences |
| 07 Nov 2024 | Announcement | Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |